Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 2/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510820 | 0.92 | ALDH1A1 (0.40) | LMNACHRM2CHRM1CHRM3SLC6A2 | |
| SCHEMBL4503886 | 0.90 | SLC6A2 (0.47) | SLC6A2 | |
| SCHEMBL3961040 | 0.86 | OPRD1 (0.38) | LMNACHRM2CHRM1CHRM3SLC6A2 | |
| SCHEMBL3960353 | 0.86 | SLC6A2 (0.44) | LMNASLC6A2SLC6A4MAPK1 | |
| SCHEMBL3957574 | 0.86 | CHRM3 (0.35) | LMNACHRM2CHRM1CHRM3SLC6A2 | |
| SCHEMBL4500522 | 0.86 | SLC6A2 (0.48) | LMNACHRM2CHRM1CHRM3SLC6A2 | |
| SCHEMBL4497752 | 0.85 | SLC6A2 (0.45) | SLC6A2 | |
| SCHEMBL4493804 | 0.85 | SLC6A2 (0.45) | SLC6A2 | |
| SCHEMBL3956007 | 0.83 | CNR1 (0.34) | LMNACHRM2CHRM1CHRM3SLC6A2 | |
| SCHEMBL3957323 | 0.83 | SLC6A3 (0.38) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | LMNA 1130/4885CHRM2 482/4885CHRM1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.